Giant drug manufacturer GlaxoSmithKline announced today that it intends to stop paying doctors to prescribe more of the company’s drugs, a move that could possibly entice other large pharma companies to do the same. [More]
The lower prices that come from competition when drug patents expire and generic versions hit the market is great for consumers, but do you know what’s terrible for consumers? Drugs that don’t work. Yet there may be drugs on your shelf at home right now that haven’t been proven safe, effective, and––in the case of generics–– equivalent to the original brand-name drug. The alleged poor practices by six chemists at one research company in Texas affected more than one hundred drugs on the market in the United States and Europe. [More]
Yesterday, pharma biggie GlaxoSmithKline settled for $3 billion with the Justice Dept. over a wide range of fraud-related allegations. Among all the documents involved in the case are claims by the DOJ that GSK paid TV/Radio personality Dr. Drew Pinsky a pile of cash to talk up off-label uses of the company’s antidepressant Wellbutrin, including a purported tie to causing multiple orgasms in females. [More]
What do those little letters, CD, ER, SR, etc, after a brand name drug’s name mean? The exact terminology varies, but they usually translate to the same thing: unnecessary ripoffs.
A class action lawsuit has been filed accusing GlaxoSmithKline of lying to the Patent office and dickering with fake patent litigation against generic drug makers to fraudulently stymie generic versions of Wellbutrin from hitting the market. The lawsuit applies to people who directly bought Wellbutrin from GSK in 100 or 150mg hits between Jan 24, 2002 and June 30, 2006. Obviously, the long GSK could keep a generic version of their drug off the market, the more money they could make. People interested in joining could probably contact the firm of Roda and Nast, lead plaintiff team, for more information.